GlassScriptPhysician profile
Paul B Lang
NPI 1780679001
$25,332.29
in general payments reported to CMS, 2019-2025
46 companies · $4,893 in 2025
The $4,893 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,541 · 2020: $1,438 · 2021: $2,891 · 2022: $3,703 · 2023: $5,096 · 2024: $4,771 · 2025: $4,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,549.25 |
| Education | $210.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,155.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $3,003.21 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $2,959.76 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $2,444.75 | 2019-2025 | |
| Pfizer INC. | $1,657.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,317.56 | 2019-2025 | |
| Optinose US, INC. | $1,258.94 | 2019-2025 | |
| Amgen INC. | $1,091.45 | 2021-2025 | Tezspire, Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $1,037.81 | 2020-2025 | Cuvitru, Eohilia |
| Genentech USA, INC. | $1,017.66 | 2019-2025 | Xolair |
| Kaleo, INC. | $572.17 | 2020-2024 | Auvi-Q |
| Grifols USA, LLC | $559.82 | 2019-2025 | Xembify |
| Abbvie INC. | $323.46 | 2021-2025 | |
| Mylan Specialty L.P. | $318.91 | 2019-2024 | Yupelri |
| Incyte Corporation | $296.86 | 2021-2025 | Opzelura, Opzelura |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $279.85 | 2020-2024 | Cutaquig |
| Ars Pharmaceuticals Operations, INC. | $278.25 | 2025 | Neffy |
| Blueprint Medicines Corporation | $230.52 | 2023-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.26 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Sanofi-Aventis U.S. LLC | $220.27 | 2021-2024 | |
| Csl Behring | $216.06 | 2023-2025 | Hizentra |
| Insmed, INC. | $200.26 | 2024-2025 | Brinsupri, Arikayce |
| Bio Products Laboratory USA, INC. | $186.26 | 2019-2023 | Gammaplex, Coagadex |
| Shire North American Group INC | $186.03 | 2019 | |
| Covis Pharma Gmbh | $151.04 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $142.52 | 2021-2024 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $131.60 | 2020-2022 | |
| Pharming Healthcare, INC. | $126.39 | 2019-2025 | Ruconest |
| Aimmune Therapeutics, INC. | $110.06 | 2020-2022 | |
| Lilly USA, LLC | $89.32 | 2024-2025 | Ebglyss |
| Phadia US INC. | $74.40 | 2020-2024 | Immunocap |
| Sunovion Pharmaceuticals INC. | $65.83 | 2019 | |
| Verona Pharma, INC. | $62.18 | 2025 | Ohtuvayre |
| Philips North America LLC | $47.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $44.36 | 2021-2023 | |
| Eyevance Pharmaceuticals LLC | $40.33 | 2021 | |
| Leo Pharma INC. | $37.92 | 2024-2025 | Adbry, Anzupgo |
| Circassia INC. | $31.26 | 2019-2021 | |
| Gc Biopharma USA, INC. | $23.07 | 2024 | Alyglo |
| Biocryst US Sales Co., LLC | $22.79 | 2024 | Orladeyo |
| Adma Biomanufacturing LLC | $17.76 | 2021 | |
| Aytu Biopharma, INC. | $17.42 | 2023 | Karbinal |
| Mylan Pharmaceuticals INC. | $17.16 | 2020 | |
| Galderma Laboratories, L.P. | $14.93 | 2025 | Nemluvio |
| Sanofi Pasteur INC. | $14.03 | 2019 | |
| Encore Dermatology INC. | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.